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We recently isolated and characterized the new strain Bacteroides xylanisolvens DSM 23964 and pre-
sented it as potential candidate for the ﬁrst natural probiotic strain of the genus Bacteroides. In order
to evaluate the safety of this strain for use in food, the following standard toxicity assays were conducted
with this strain in both viable and pasteurized form: in vitro bacterial reverse mutation assay, in vitro
chromosomal aberration assay, and 90 day subchronic repeated oral toxicity studies in mice. No muta-
genic, clastogenic, or toxic effects were detected even at extremely high doses. In addition, no clinical,
hematological, ophthalmological, or histopathological abnormality could be observed after necropsy at
any of the doses tested. Hence, the NOAEL could be estimated to be greater than 2.3  1011 CFUs, and
2.3  1014 for pasteurized bacteria calculated as equivalent for an average 70 kg human being. In addi-
tion, the absence of any in vivo pathogenic properties of viable B. xylanisolvens DSM 23964 cells was con-
ﬁrmed by means of an intraperitoneal abscess formation model in mice which also demonstrated that the
bacteria are easily eradicated by the host’s immune system. The obtained results support the assumed
safety of B. xylanisolvens DSM 23964 for use in food.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction the identiﬁcation and development of other probiotic strains withProbiotics are live microorganisms, which, when administered
in adequate numbers, confer a health beneﬁt on the host (FAO/
WHO, 2001; Guarner et al., 2005). Therefore, microbes used as pro-
biotics may theoretically originate from any genera and species.
However, besides conferring a health beneﬁt to the host, a probi-
otic strain must ﬁrst of all be shown to be safe at intended levels
of use in food. Although probiotic strains belonging to species com-
monly found in fermented food are generally recognized as safe,
strains belonging to nontraditional species may evoke greater con-
cern about potentially adverse effects (Franz et al., 2003; Lund and
Edlund, 2001), and therefore should be subject to an appropriate
series of studies to demonstrate safety. As a consequence, research
in the probiotic ﬁeld has so far concentrated on traditional bacte-
rial species (Sanders et al., 2010). This focus, however, may deterY-NC-ND license. 
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The genus Bacteroides may provide a source of interesting pro-
biotic strains. First, this genus is the second most abundant in
the human gut microbiota, surpassing Lactobacillus and Biﬁdobacte-
rium by a factor of 10,000 (Hayashi et al., 2002, 2007). Further-
more, it has been reported to possess many metabolic and
immunomodulatory activities that may be beneﬁcial for the hu-
man body (Troy and Kasper, 2011; Dasgupta and Kasper, 2010;
Comstock, 2009). However, despite this diversity and great poten-
tial, this genus did not attract much attention within the probiotic
research community. In a recent study, we isolated a new Bacteroi-
des strain (DSM 23964) from feces of healthy human individuals
which belongs to the non-pathogenic species B. xylanisolvens
(Ulsemer et al., 2011, in press). We demonstrated that it is (i) resis-
tant towards the action of enzymes of the gastric and intestinal
juice, (ii) sensitive to antibiotics, (iii) unlikely to transfer or acquire
antibiotic resistance, and (iv) free from any of the virulence activ-
ities described for the genus Bacteroides. These results suggested
the strain B. xylanisolvens DSM 23964 to be free of any virulence
factors that would preclude it from being considered for further
investigations, and eventually leading to the development of the
ﬁrst natural probiotic strain of the genus Bacteroides. However,
for a complete safety assessment, further in vitro and in vivo
analyses are still required.
Accumulating evidence suggests that, depending on the molec-
ular mechanisms involved, killed probiotic strains may confer the
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et al., 2009; Adams, 2010). Furthermore, the development of new
functional ingredients based on an inactivated probiotic strain
would (i) greatly facilitate its production and storage, (ii) expand
its application possibilities, (iii) allow more correct estimation of
dosage and shelf life data, and (iv), perhaps most importantly,
avoid concerns about possible unwanted side effects that may be
accompanied with the chronic intake of any living probiotic strain
(Kataria et al., 2009; Fuller, 1989; Adams, 2010). Therefore, pro-
vided that the health beneﬁt conferred by the strain B. xylanisolvens
DSM 23964 is conserved after heat inactivation, it may be highly
advantageous to commercialize it in inactivated form. Hence, and
because some studies have revealed adverse effects resulting from
the ingestion of heat killed probiotics (Kirjavainen et al., 2003), it is
prudent that the safety of both the viable and the heat-inactivated
bacteria be demonstrated.
This study presents the results of in vitro and in vivo toxicolog-
ical and pathological analyses of the strain B. xylanisolvens DSM
23964 in both its viable and heat-inactivated (pasteurized) form.2. Materials and methods
2.1. Bacterial strains
2.1.1. Test items
B. xylanisolvens DSM 23964 was cultured in Wilkins–Chalgren
broth medium under anaerobic conditions, harvested by centrifu-
gation, and lyophilized. The lyophilized B. xylanisolvens DSM
23964 material was used for the genotoxicity and oral toxicity
studies. It contained 4  109 CFU/g (referred to as ‘‘viable bacte-
ria’’). The lyophilized preparation of pasteurized B. xylanisolvens
DSM 23964 contained 1.7  1012 cells/g (referred to as ‘‘pasteur-
ized bacteria’’). Viability, purity and bacterial concentration of
lyophilized bacterial strains were analyzed under GLP conditions
by BIOTECON GmbH (Potsdam, Germany). For the in vivo pathoge-
nicity study (abscess formation), fresh overnight cultures of Bacte-
roides fragilis RMA 6971, a clinical isolate obtained from the
collection of the Institute for Medical Microbiology at the Univer-
sity of Leipzig, Germany, and of B. xylanisolvens DSM 23964 were
harvested, washed, resuspended in PBS (5.28 g Na2HPO4, 1.44 g
KH2PO4, 90 g NaCl per liter, pH 7.4), and mixed with 50% (w/w)
autoclaved rat feces and 10% (w/v) barium sulfate to ﬁnal concen-
trations of 5.0  106, 1.5  108, and 1.0  109 CFUs/ml for B. fragilis
RMA 6971 and B. xylanisolvens DSM 23964.
2.2. In vitro mutagenicity study (Ames test)
This study was conducted at the Laboratory of Pharmacology
(Hamburg, Germany) under GLP standards and according to the
OECD guideline and the EC directive 2000/32/EC.
2.2.1. Tester strains
The following Salmonella typhimurium strains were obtained
from Dr. Bruce N. Ames: TA 98 and TA 1537, which primarily re-
spond to frameshift mutagens, and TA 100, TA 102 and TA 1535
which respond to base-pair substitution mutagens. In addition to
the mutation in the histidine operon, these strains contain several
other mutations that greatly increase their ability to detect
mutagens.
2.2.2. Metabolic activation system
Post-mitochondrial fraction (S9 fraction) from rats treated with
Aroclor 1254 (Analabs, North Haven, CT, USA) was prepared
according to Maron and Ames (1983). Brieﬂy; S9 was prepared
from the livers of 20–30 rats. The pooled fraction was tested forits protein content according to Lowry et al. (1951) and for its P-
450 content according to Mazel (1971). The values were 38.2 mg/
mL protein and 1.97 nmol cytochrome P-450/mg protein, respec-
tively. The S9 fraction was stored in liquid nitrogen. The 5% S9
mix was freshly prepared on the day of the test as follows:
5.0 mL rat liver fraction S9 (Aroclor 1254-induced), 2.0 mL 0.4 M
MgCl2 + 1.65 M KCl solution (sterile stock solution), 141.0 mg glu-
cose-6-phosphate, 306.5 mg NADP, 50.0 mL 0.2 M phosphate buf-
fer, pH 7.4 (sterile stock solution), and sterile aqua ad injectabilia
ad 100 ml. Afterwards, the S9 mix was ﬁlter-sterilized by using a
0.45 lm ﬁlter and then kept on ice.
2.2.3. General methods
The lyophilized bacteria (viable and pasteurized cultures of B.
xylanisolvens DSM 23964) were suspended in sterile 0.8% aqueous
hydroxypropyl-methylcellulose solution (Fargon, Germany) under
anaerobic conditions shortly before the start of the test. The sterile
0.8% hydroxypropylmethylcellulose solution (referred to as ‘‘vehi-
cle’’) was degassed in an anaerobic jar (Oxoid, Wesel, Germany)
with an anaerobic bag (Oxoid) for 24 h before use. Pasteurized bac-
teria were suspended to a ﬁnal concentration of 118 mg/ml. Viable
bacteria were suspended at concentrations of 57.0, 17.0, 5.8, 1.7,
and 0.56 mg/ml. The vehicle alone served as negative control.
Two independent experiments were carried out each with and
without S9 activation; each experiment consisted of three plates
per concentration and strain. Metabolic activation was performed
with a liver post-mitochondrial fraction (S9 fraction) from Aroclor
1254-treated rats. The positive controls used in this study were: (i)
without S9 activation: sodium azide (Sigma, Taufkirchen,
Germany) in H2O was added for strains TA100 and TA1535
(10 mg/plate), 2-nitroﬂuorene (Riedel de Häen, Seelze, Germany)
in DMSO (Merck, Darmstadt, Germany) was applied for strain
TA98 (10 lg/plate), 9-aminoacridine (Merck) in ethanol was
employed for strain TA1537 (100 lg/plate), and methyl methane
sulfonate (Merck) in DMSO was added for strain TA102 (1300 lg/
plate); (ii) with S9 activation: 2-amino-anthracene (Oxoid) for
strains TA98, TA102 and TA 1537 (2 lg/plate), and cyclophospha-
mide (Sigma) in aqua ad injectabilia (Delta) for strains TA100 and
TA1535 (1500 mg/plate).
2.2.4. Plate incorporation test
Sterile top agar containing 0.6% agar and 0.5% NaCl was molten
on the day of the test. Ten ml of a sterile solution of 0.5 mM L-his-
tidine HCl and 0.5 mM biotin were added to 100 ml of molten agar.
Two milliliter of this top agar were distributed into culture tubes
held at 45 C in a heating block. Salmonella cell suspension
(0.1 ml, containing approximately 108 viable cells in the late expo-
nential or early stationary phase), 0.5 ml of test item suspension
(or 0.5 ml solvent, or 0.1 ml positive control), and 0.5 ml of S9
mix were added to the culture tubes. In the assay without meta-
bolic activation, the S9 mix was substituted with 0.5 ml sterile
PBS. The test components were mixed and then poured onto a
Vogel–Bonner medium E minimal glucose agar plate. The plates
were inverted and incubated for 48–72 h at 37 C. The revertant
colonies on the test plates and on the control plates were counted
with a colony counter, and the presence of the background lawn on
all plates was conﬁrmed. A lawn that was thin compared with the
lawn on the negative control plate was considered as evidence of
bacterial toxicity.
2.2.5. Pre-incubation test
The test item and test suspension with the Salmonella tester
strain (containing approximately 108 viable cells in the late expo-
nential or early stationary phase) and sterile PBS or the metabolic
activation system were pre-incubated for 20 min at 37 C prior to
mixing with the overlay agar and pouring it onto the surface of a
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Salmonella tester strain suspension and 0.5 ml of S9 mix or sterile
PBS were mixed with 2 ml of overlay agar. Tubes were aerated dur-
ing pre-incubation by using a shaker. The remaining steps were the
same as described for the plate incorporation method.
For the statistical evaluation of the results a test item was con-
sidered to show a positive response, if (i) the number of revertants
was signiﬁcantly increased (p 6 0.05, U-test according to
Colquhoun, 1971) compared with the solvent control (at least
2-fold increase for TA 98, TA 100 and TA 102, and at least 3-fold
increase for TA 1535 and TA 1537) in both experiments, and (ii)
in addition, a signiﬁcant (p 6 0.05) concentration (log value)-
related effect (Colquhoun) was observed. Positive results had to
be reproducible, and the histidine independence of the revertants
had to be conﬁrmed by streaking random samples on histidine-free
agar plates. Cytotoxicity was deﬁned as a reduction in the number
of colonies by more than 50% compared with the solvent control
and/or a scarce background lawn.2.3. In vitro assessment of the clastogenic activity (in vitro
chromosomal aberration assay)
This test was conducted by the Laboratory of Pharmacology
(Hamburg, Germany) under GLP standards and according to OECD
guideline 437, EC directive 2000/32/EC, and ICH guideline S2B:
(CPMP/ICH/174/95).2.3.1. Metabolic activation system
A ‘S9 mix’ (prepared according to 2.2.2.) containing 10% rat liver
post-mitochondrial fraction S9 was prepared.2.3.2. Source of blood and culture conditions
Human peripheral blood was obtained by venipuncture from
healthy human donors known to be not on any medication, and
collected in heparinized vials. Small inocula of whole blood
(0.5 ml) were added to tubes containing 4.5 ml of complete culture
medium (500 ml chromosome medium 1A with phytohemaggluti-
nin and 5 ml penicillin/streptomycin [10,000 IU/mL]). The tubes
were sealed and incubated for 48 h at 37 C with occasional shak-
ing to prevent clumping. The cell pellets were resuspended in
4.0 ml treatment medium (500 ml Ham’s F-10 and 13.1 ml fetal
calf serum) with 0.5 ml S9 mix, or in 4.5 ml treatment medium
including the test item at the ﬁnal concentrations indicated above.
The tubes were incubated for 4 h in a shaking water bath at 37 C.
After this period, the tubes were centrifuged, and the cells were
washed with 5 ml of treatment medium to remove the test item
and S9 mix. After a further centrifugation the cell pellet was resus-
pended in 5 ml of complete medium, and incubated for a further
20 h.2.3.3. Preliminary toxicity study
A preliminary toxicity study was conducted to establish the top
concentration for the main cytogenetic test. Each treatment was
tested in the absence and in the presence of S9 mix. One thousand
lymphocytes per culture were examined at a magniﬁcation of
400; the mitotic index was calculated as the percentage of exam-
ined lymphocytes which were in mitosis (metaphase). The clasto-
genic activity of the following doses of test items was analyzed:
5.9 mg pasteurized bacteria/ml vehicle, or 0.028, 0.085, 0.29, 0.85
and 2.8 mg viable bacteria/ml vehicle. Mitomycin C (Sigma) was
used as positive control for the study in the absence of metabolic
activation, and cyclophosphamide (Sigma) as the positive control
for the study in the presence of metabolic activation. The vehicle
was used as negative reference item.2.3.4. Main study
In a second set of experiments a continuous treatment of 24 h
without metabolic activation was carried out, and the 4 h treat-
ment with metabolic activation was repeated. Two hours before
termination cell division was arrested by the addition of 0.5 ml
of a 10 lg/ml solution of the spindle poison colcemid (Fluka, Buchs,
Switzerland) to each culture. The tubes were capped and incubated
for a further two hours. The cells were harvested by centrifugation
at 80–100g, and the cell pellets were resuspended in hypotonic
potassium chloride solution (0.56%) for 17 min. Following another
centrifugation step of 10 min the cells were ﬁxed in freshly pre-
pared methanol/glacial acetic acid ﬁxative (4:1, v/v). For each
treatment and culture 100 metaphases were examined. All cul-
tures were run in duplicate using blood from different donors.
The observed aberrations were noted and scored according to Sa-
vage (1976). In addition, the total number of gaps was recorded
in 100 metaphases for each culture. Metaphases which differed
from the normal diploid complement (46 cases) were excluded
from evaluation. However, test item-related variations of the nor-
mal chromosome number were noted (polyploidy/endoreduplica-
tion). To examine the toxicity of the test item 1000 cells were
scored, and the mitotic index was calculated as percentage of cells
in metaphase.
For a statistical evaluation the assessment was carried out by
comparing the number of chromosome aberrations of the samples
with those of the control, using the recommendations of the
UKEMS guideline (Kirkland, 1989). In this study, therefore, only
the total numbers of cells with aberrations (except of gap dam-
ages) were analyzed. The test item was judged as having muta-
genic properties with respect to chromosomal or chromatid
change, if: (i) the number of chromosomal aberrations was signif-
icantly increased (p 6 0.05) compared with the control, (ii) the in-
crease observed was concentration-dependent, (iii) both duplicate
cultures led to similar results; (iv) the increase did not occur in the
severely cytotoxic range (mitotic index < 0.25), as it was known
that high cytotoxicity causes artifacts, and (v) a reproducible in-
crease in the number of cells with chromosomal aberrations was
observed.
2.4. Ninety-day oral toxicity study in mice
This study was conducted by the Laboratory of Pharmacology
(Hamburg, Germany) under GLP standards and according to EC
2001/59/EC B.26 as well as the OECD guideline No. 408.
Hundred Crl:NMRI mice (50 male and 50 female) supplied by
Charles River Laboratories (Sulzfeld, Germany) were weighed and
allocated by means of a computerized randomization program to
each of the ﬁve test groups (10 males and 10 females per group).
The approximate age of animals was 6–7 weeks at the initiation
of dosing. The animals were kept singly in macrolon cages (type
I) with granulated textured wood bedding at a room temperature
of 22 C ± 3 C (maximum range) and a relative humidity of
55% ± 15% (maximum range). The cages were changed and cleaned
once a week. Commercial ssniff R/M-H V1530 (ssniff Spezialdiäten
GmbH, 59494 Soest, Germany) served as food. Food and water
were offered ad libitum. Periodic analysis of the food and drinking
water for contaminants were conducted based according to EPA/
USA rules (Proposed Health Effects Test Standards for Toxic Sub-
stances Control Act Test Rules, Federal Register 44, 27334–27375,
May 1979) on a routine basis by LUFA-ITL (Landwirtschaftliche
Untersuchungs- und Forschungsanstalt, Institut für Tiergesundheit
und Lebensmittelqualität GmbH, 24107 Kiel, Germany). Certiﬁ-
cates of analysis of the composition and for contaminants were
provided by the manufacturer. The test item-vehicle mixtures
were freshly prepared each day. Based on the determined bacteria
concentration (see ‘‘test items’’), lyophilized test items were
Table 1
Experimental groups for intraperitoneal abscess formation.
Group Bacterial strain Dose (CFU/ml) Number of animals
Dissection on day 7
1 Negative control – 4
2 B. fragilis RMA 6971 1.0  109 4
3 B. xylanisolvens DSM 23964 1.0  109 4
4 B. fragilis RMA 6971 1.5  108 4
5 B. xylanisolvens DSM 23964 1.5  108 4
6 B. fragilis RMA 6971 5.0  106 3
7 B. xylanisolvens DSM 23964 5.0  106 3
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2  108 CFUs of B. xylanisolvens DSM 23964 per ml 0.8% aqueous
hydroxypropylmethylcellulose gel (referred to as ‘‘vehicle’’), or
2  1011 pasteurized B. xylanisolvens DSM 23964 per ml under
anaerobic conditions. A daily amount of 0.5 ml of the test item-
vehicle mixtures was dosed orally by gavage to each mouse. One
group of mice (control group) received the vehicle without bacte-
ria. Daily cage-side observations focused on skin/fur, eyes, mucous
membranes, respiratory and circulatory systems, motor activity,
and behavioral pattern. Additionally, once before the ﬁrst exposure
(to allow for within-subject comparisons) and once a week there-
after (1, 2, 4, 8 and 24 h after administration), detailed clinical
observations were made on all animals. Changes in gait, posture
and response to handling as well as the presence of clonic or tonic
movements, stereotypies or bizarre behavior were also recorded.
The body weights were recorded at the time of allocation of ani-
mals to groups, on the day of commencement of treatment, and
subsequently in weekly intervals. All surviving animals were killed
by exsanguination under light ether anesthesia after at least
90 days of dosing. Blood samples were collected at termination
for hematological and clinical chemical examinations (Tables 5
and 6). The following instrumentation was used for hematological
and biochemical analysis: for hematology ADVIATM 120 (Siemens
diagnostics GmbH, Fernwald, Germany), for coagulation AMAX
Destiny (Trinity Biotech GmbH, Lemgo, Germany), and for
biochemistry KONELAB 30i (Thermo ﬁsher scientiﬁc, Dreieich,
Germany). All animals were subjected to gross necropsy and the
weight of the main organs was recorded (Table 7). Histopatholo-
gical examination of the main organs and tissues (Table 8) was
performed on all animals of groups 1, 4 and 5.
Data on all functional tests were analyzed by Student’s t-test.
Data on hematological and clinicochemical parameters, body
weight, food consumption, and organ weight were evaluated for
treatment-related differences by Dunnett’s multiple comparison
tests. Histological changes were examined by Fischer’s exact prob-
ability test.
2.5. In vivo pathogenicity of B. xylanisolvens DSM 23964 (abscess
formation)
This study was conducted by the Laboratory of Pharmacology
(Hamburg, Germany). Twenty-six male Swiss Webster mice
(Taconic Europe A/S, Denmark), weighing between 35.5 and 52.6 g,
were divided in seven groups (Table 1). The approximate age of
the animalswas19 weeks at the timeof administration. The animals
were kept singly inmacrolon cages (type I)with granulated textured
wood bedding at a room temperature of 22 C ± 3 C (maximum
range) and a relative humidity of 55% ± 15% (maximum range). Five
gramof fresh feces from six untreated CD rats (male)were collected,
suspended in 50 ml of sterile PBS and sterilized in an autoclave. After
centrifugation (15 min at 750g), the supernatant was collected,
autoclaved again, tested for sterility, and stored at 20 C until
use.B. fragilisRMA6791 (positive control), and the test itemB. xylan-
isolvens DSM 23964 were cultured inWilkins–Chalgren broth med-
ium for 24–48 h at 37 C under anaerobic conditions. Shortly before
the start of the experiments the cultures were centrifuged. The bac-
terial pellets were washed with 0.85% NaCl solution, and collected
and stored at 37 C under anaerobic conditions. The mice received
intraperitoneally 200 ll of a test item-mixture solution (see test
items) containing bacteria at a concentration ranging from 5  106
to 1  109 CFUs/ml (Table 1). Following application, the remaining
suspensions were tested to ensure the microbiological purity of
the test solutions at the time of injection. For this purpose, the undi-
luted bacterial suspensions were plated on appropriate agar plates
and incubated 24–48 h at 37 C under aerobic and anaerobic condi-
tions. A sample from each plate was scraped and submitted to DNAextractionusingDNeasyBlood&TissueKit (Qiagen) according to the
manufacturer’s protocol. Using the isolated DNA,multiplex species-
speciﬁc PCRswere performed as described by Liu et al. (2003). For B.
xylanisolvens, the primers and conditions described for the species
Bacteroidesovatus revealed a single andB.xylanisolvens-speciﬁcband
of about 820 bp. The multiplex PCR assay detected 300–500 cells.
Animalswere dissected after 7 days and examined for intra-abdom-
inal abscesses. Two abscesses per animal of each group were re-
moved under sterile conditions. Abscesses were punctured, and
the abscess contents submitted to DNA extraction. Species-speciﬁc
PCR as described above was applied for detecting the administrated
bacteria.
3. Results
3.1. Viability assay
The viability of B. xylanisolvens DSM 23964 after lyophilization
and rehydration was analyzed in several independent experiments.
The lowest identiﬁed survival rate indicated a minimum concen-
tration of 4  109 CFU/g viable bacteria. This concentration was
considered as the ‘‘available concentration’’.
3.2. In vitro mutagenicity study (Ames test)
This test was performed to detect any toxic or mutagenic effects
of the B. xylanisolvens DSM 23964. Five doses of viable bacteria
ranging from 0.28 to 28.5 mg/plate or one dose of 59 mg of pas-
teurized bacteria/plate were applied in two independent experi-
ments, each carried out with and without metabolic activation.
No signs of cytotoxicity and no increase in revertant colony num-
bers as compared with control counts were observed for any con-
centration of the ﬁve test strains with and without metabolic
activation, and also in plate incorporation as well as in pre-incuba-
tion mode, respectively (Table 2).
3.3. In vitro assessment of the clastogenic activity (in vitro
chromosomal aberration assay)
The top concentration of B. xylanisolvens DSM 23964 employed
in the study was 2.8 mg viable or 5.9 mg pasteurized bacteria/ml
sterile 0.8% aqueous hydroxypropyl-methylcellulose, which were
considered to be the maximum reasonable concentration. As
shown in Table 3, in the absence of metabolic activation, the mean
incidence of chromosomal aberrations (excluding gaps) observed
in the negative control was 1.0% or 0.5% after a 4-h or 24-h expo-
sure, respectively. None of the concentrations of B. xylanisolvens
DSM 23964, either viable or pasteurized, produced any statistically
signiﬁcant increase in aberrant cells from 0.5% to 2.5% after 4-h or
24-h exposure. In contrast, the positive control presented a 10.5%
or 17.5% increase in aberrant cells after a 4-h or 24-h exposure,
respectively. As presented in Table 4, in the presence of metabolic
activation, the mean incidence of chromosomal aberrations
Table 2
Summary of reverted colonies of Salmonella typhimurium (Ames test) with and without metabolic activation with S9.
Test item TA 98 TA 100 TA 102 TA 1535 TA 1537
(+S9) (S9) (+S9) (S9) (+S9) (S9) (+S9) (S9) (+S9) (S9)
Plate incorporation
DSM 23964
(past.)a
37 ± 3.6 35.3 ± 4.5 157 ± 5.6 155.7 ± 5.7 270 ± 16.7 269 ± 4.6 23.7 ± 2.3 27.3 ± 11 8.3 ± 2.1 8.7 ± 2.3
DSM 23964
(viable)b
39.7 ± 4.2 34 ± 1 156.7 ± 6 159 ± 15.7 266 ± 21.7 267 ± 13.1 16.7 ± 3.2 29.7 ± 0.6 9.7 ± 0.6 6.7 ± 2.3
Negative control c 33.3 ± 4.9 32.7 ± 5.7 169 ± 11.4 160.3 ± 12.1 267 ± 13.1 280 ± 20 22 ± 4 31 ± 3.6 9.7 ± 0.6 9 ± 1
Positive control 451 ± 11d 685 ± 7.5f 748.3 ± 3.2e 774 ± 25.1g 1172 ± 7d 1185 ± 3.5h 266.7 ± 3.8e 262 ± 7.2g 194 ± 15.7d 194 ± 17.3i
Preincubation
DSM 23964
(past.)a
30.3 ± 2.5 35.3 ± 4.5 132.3 ± 9.2 155.7 ± 5.7 264 ± 2.6 269 ± 4.6 16.3 ± 3.8 27.3 ± 11 4.7 ± 0.6 8.7 ± 2.3
DSM 23964
(viable)b
26.3 ± 1.5 28 ± 1 117.3 ± 6.7 130.7 ± 4 252.3 ± 14.5 269 ± 4 12.7 ± 2.1 20 ± 2 5.3 ± 3.1 6.3 ± 1.5
Negative control c 38 ± 6 31 ± 4.4 147.3 ± 4.2 152.7 ± 11.6 285.3 ± 5.5 288.3 ± 3.5 17.3 ± 3.1 20 ± 2 8.3 ± 1.5 8.7 ± 0.6
Positive control 441 ± 12d 689 ± 2.1f 1050 ± 11.3e 1020 ± 12.7g 1042 ± 46.8d 1145.7 ± 6.8h 379.7 ± 2.1e 410.3 ± 8.1g 177 ± 12.5d 166.3 ± 4i
Data are presented as Mean of revertant colony numbers ± SEM.
a DSM 23964 (past.) at 59 mg/plate.
b DSM 23964 (viable) at 25 mg/plate.
c Hydroxypropylmethylcellulose at 100 ll/plate.
d 2-Amino-anthracene at 2 lg/plate.
e Cyclophosphamide at 1500 mg/plate.
f 2-Nitroﬂuorene at 10 lg/plate.
g Sodium-azide at 10 mg/plate.
h Methyl methane sulfonate at 1300 lg/plate.
i 9-Aminoacridine at 100 lg/plate.
Table 4
Summary of in vitro chromosome analyses in human peripheral lymphocytes with metabolic activation.
Test item Concentration (mg bacteria/ml) 1st Experiment 2nd Experiment
4 h Exposure 4 h Exposure
Mitotic index
a
Metaphases
scored
Aberrant cells
(%)
Mitotic
index
Metaphases
scored
Aberrant cells
(%)
DSM 23964
(viable)
0.085 1.06 200 1.5 1.10 200 1.5
0.29 1.00 200 0.0 0.99 200 1.5
0.85 1.06 200 0.5d 1.09 200 1.0
2.8 0.92 200 0.5 0.98 200 1.0d
DSM 23964
(past.)
5.9 0.92 200 1.0 1.10 200 0.5
Positive controlb 0.54 200 13.5* 1.05 200 16.5*
Negative controlc 1.00 200 0.5d 1.00 200 0.5
a Number of metaphases/1000 cells.
b Cyclophosphamide (10 lg/ml in 1st experiment; 20 lg/ml in 2nd experiment).
c 0.8% Aqueous hydroxypropylmethylcellulose.
d Tetraploidy (excluded from evaluation).
* Signiﬁcantly different from negative control (p 6 0.05).
Table 3
Summary of in vitro chromosome analysis in human peripheral lymphocytes without metabolic activation.
Test item Concentration (mg bacteria/ml) 1st Experiment 2nd Experiment
4 h Exposure 24 h Exposure
Mitotic index a Metaphases scored Aberrant cells (%) Mitotic index Metaphases scored Aberrant cells (%)
DSM 23964 (viable) 0.085 1.15 200 1.5 0.95 200 2.0
0.29 0.91 200 1.0d 1.02 200 1.0
0.85 0.91 200 1.5d 1.22 200 2.5d
2.8 1.09 200 2.0 0.76 200 1.0
DSM 23964 (past.) 5.9 0.98 200 1.5 1.03 200 0.5
Positive controlb 0.76 200 10.5* 0.72 200 17.5d,*
Negative controlc 1.00 200 1.0 1.00 200 0.5
a Number of metaphases/1000 cells.
b Mitomycin C (0.1 lg/ml in 1st experiment; 0.2 lg/ml in 2nd experiment).
c 0.8% Aqueous hydroxypropylmethylcellulose.
d Tetraploidy (excluded from evaluation).
* Signiﬁcantly different from negative control (p 6 0.05).
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Table 5
Summary of hematological values in the mice subchronic 90-day oral toxicity study.
Females HgB (mmol/L) RBC (1012/L) WBC (109/L) Retic (%) PCT (109/L) Neut (109/L) Lym (109/L) Mono (109/L) Eos (109/L)
Group 1a 10.20 ± 0.48 10.22 ± 0.33 5.02 ± 2.64 25.40 ± 3.21 1275.4 ± 183.6 0.996 ± 0.92 3.892 ± 2.7 0.036 ± 0.02 0.058 ± 0.026
Group 2b 9.82 ± 0.79 9.84 ± 0.65 2.60 ± 0.68 27 ± 2.24 1122.6 ± 158 0.328 ± 0.042 2.17 ± 0.59 0.022 ± 0.016 0.056 ± 0.042
Group 3c 10.46 ± 0.3 10.2 ± 0.44 4.9 ± 2.55 27.2 ± 10.35 1394.2 ± 235.3 0.586 ± 0.35 4.128 ± 2.18 0.068 ± 0.036 0.094 ± 0.055
Group 4d 10.08 ± 0.33 9.86 ± 0.43 4.98 ± 1.53 26.40 ± 4.83 1349.6 ± 218.7 0.432 ± 0.2 4.332 ± 1.433 0.024 ± 0.009 0.162 ± 0.119
Group 5e 10.26 ± 0.26 10.06 ± 0.19 5.28 ± 2.35 29.8 ± 3.35 1261 ± 160.3 0.352 ± 0.124 4.730 ± 2.18 0.044 ± 0.043 0.086 ± 0.042
Females LUC (109/L) Baso (109/L) Hct (%) PT (s) APTT (s) MCV (fL) MCH (pg) MCHC (g/l)
Group 1 0.016 ± 0.018 0.010 ± 0.007 48.8 ± 1.6 7.52 ± 0.4 24.42 ± 2.45 47.48 ± 1.06 16.08 ± 0.59 338.8 ± 6.9
Group 2 0.006 ± 0.005 0.006 ± 0.005 47.6 ± 2.9 7.80 ± 0.44 24.98 ± 4.94 48.26 ± 1.4 16.08 ± 0.31 333 ± 11.9
Group 3 0.020 ± 0.014 0.004 ± 0.005 50.2 ± 1.3 7.24 ± 0.4 24.12 ± 3.07 49.28 ± 1.9 16.56 ± 0.6 336.3 ± 2.25
Group 4 0.012 ± 0.008 0.010 ± 0.007 47.8 ± 1.3 7.46 ± 0.18 23.44 ± 1.33 48.64 ± 1.87 16.5 ± 0.52 339.6 ± 9.25
Group 5 0.022 ± 0.016 0.008 ± 0.008 48.6 ± 0.9 7.62 ± 0.26 21.1 ± 1.85 48.22 ± 0.86 16.43 ± 0.5 340.5 ± 7.77
Males HgB (mmol/L) RBC (1012/L) WBC (109/L) Retic (%) PCT (109/L) Neut (109/L) Lym (109/L) Mono (109/L) Eos (109/L)
Group 1 9.82 ± 0.38 9.96 ± 0.38 6.58 ± 3.03 23.80 ± 2.39 1670.4 ± 162.4 0.778 ± 0.389 5.566 ± 2.546 0.106 ± 0.078 0.086 ± 0.044
Group 2 10.06 ± 0.62 10.18 ± 0.50 2.82 ± 0.96 26.20 ± 2.59 1372.8 ± 148.9 0.478 ± 0.239 2.202 ± 0.736 0.032 ± 0.030 0.060 ± 0.046
Group 3 9.98 ± 0.42 10.08 ± 0.62 5.02 ± 3.07 25.60 ± 3.91 1426.6 ± 234.1 0.818 ± 0.442 3.942 ± 2.531 0.040 ± 0.042 0.162 ± 0.204
Group 4 9.72 ± 0.50 9.98 ± 0.61 3.28 ± 1.82 26.40 ± 1.34 1538.6 ± 99.9 0.504 ± 0.354 2.692 ± 1.683 0.022 ± 0.013 0.050 ± 0.019
Group 5 9.94 ± 0.30 10.44 ± 0.27 5.78 ± 2.38 26.20 ± 2.95 1481.0 ± 218.5 0.626 ± 0.430 4.844 ± 2.105 0.058 ± 0.033 0.200 ± 0.193
Males LUC (109/L) Baso (109/L) Hct (%) PT (sec) APTT (sec) MCV (fL) MCH (pg) MCHC (g/l)
Group 1 0.028 ± 0.019 0.008 ± 0.004 47.8 ± 1.6 7.78 ± 0.28 23.14 ± 2.06 47.98 ± 0.82 15.89 ± 0.24 331.23 ± 3.7
Group 2 0.008 ± 0.008 0.004 ± 0.005 47.8 ± 2.5 7.98 ± 0.35 24.24 ± 2.45 47.10 ± 0.5 15.95 ± 0.4 339.02 ± 5.2
Group 3 0.016 ± 0.015 0.006 ± 0.005 47.8 ± 2.2 7.84 ± 0.21 23.56 ± 2.35 47.64 ± 1.11 15.98 ± 0.5 334.8 ± 3.2
Group 4 0.010 ± 0.012 0.002 ± 0.004 47.6 ± 1.8 7.54 ± 0.4 23.62 ± 1.2 47.66 ± 1.35 15.72 ± 0.54 329.8 ± 5.1
Group 5 0.018 ± 0.015 0.006 ± 0.005 48.6 ± 1.1 7.94 ± 0.18 23.76 ± 0.96 46.62 ± 0.96 15.4 ± 0.63 330.5 ± 9.1
Abbreviations: APTT, activated partial thromboplastin time; Baso, basophilic granulocytes; Eos, eosinophilic granulocytes; Hct, haematocrit value; HgB, haemoglobin content;
LUC, large unstained cells; Lym, lymphocytes; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; MCV, mean corpuscular volume;
Mono, monocytes; Neut, neutrophilic granulocytes; PCT, platelets; RBC, red blood cells; Retic, reticulocytes; ﬂ, femtoliter.
a Control.
b DSM 23964 (viable) 1  106 CFU/animal/day.
c DSM 23964 (viable) 1  107 CFU/animal/day.
d DSM 23964 (viable) 1  108 CFU/animal/day.
e DSM 23964 (past.) 1  1011 cells/animal/day.
Table 6
Summary of clinical biochemistry values in the mice subchronic 90-day oral toxicity study.
Females Albumin (g/L) Globulin(g/L) Bil.(lmol/L) Chol.(mmol/L) Creat.(lmol/L) Glu.(mmol/L) Protein(g/L) Triglyc. (mmol/L) BUN (mmol/L)
Group 1a 29.90 ± 0.76 24.50 ± 1.67 4.52 ± 0.65 2.79 ± 0.31 23.8 ± 1.6 6.00 ± 1.27 54.4 ± 1.8 0.77 ± 0.14 6.98 ± 1.27
Group 2b 31.02 ± 0.66 26.78 ± 2.98 4.08 ± 0.31 3.05 ± 0.56 22.4 ± 1.9 6.76 ± 1.04 57.8 ± 3.1 0.88 ± 0.23 6.20 ± 0.97
Group 3c 30.14 ± 1.34 26.86 ± 4.8 4.12 ± 1.02 3.06 ± 0.76 23.0 ± 2.1 6.95 ± 2.31 57.0 ± 5.2 0.72 ± 0.08 5.42 ± 1.5
Group 4d 31.06 ± 1.51 24.94 ± 2.66 4.14 ± 1.02 3.66 ± 0.28 24.4 ± 3.5 7.92 ± 2.46 56.0 ± 3.9 0.70 ± 0.135 6.26 ± 3.32
Group 5e 30.82 ± 0.75 24.38 ± 1.65 4.36 ± 0.49 3.20 ± 0.56 22.2 ± 3.8 5.756 ± 1.32 55.2 ± 1.6 0.87 ± 0.27 7.71 ± 2.01
Females Ca++(mmol/L) Cl(mmol/L) K+(mmol/L) Na+(mmol/L) ALAT(u/L) AP(u/L) ASAT(u/L) LDH(u/L)
Group 1 2.45 ± 0.11 106.0 ± 2.8 3.49 ± 0.28 147.8 ± 4.9 43.4 ± 15.6 120.6 ± 28.0 103.4 ± 23.8 265.6 ± 83.7
Group 2 2.63 ± 0.11 108.4 ± 1.5 3.74 ± 0.63 151.4 ± 1.1 24.2 ± 4.1 136.4 ± 38.9 67.4 ± 9.3 159.0 ± 35.7
Group 3 2.51 ± 0.06 108.8 ± 1.1 3.76 ± 0.39 150.8 ± 1.8 29.4 ± 5.9 112.4 ± 12.4 77.4 ± 25.8 192.4 ± 69.8
Group 4 2.59 ± 0.12 108.6 ± 1.5 3.76 ± 0.61 151.4 ± 1.1 34.0 ± 17.7 119.2 ± 21.9 62.4 ± 10.5 184.4 ± 83.5
Group 5 2.56 ± 0.15 108.2 ± 1.3 3.91 ± 0.19 150.0 ± 1.9 33.0 ± 15.0 156.6 ± 52.5 149.6 ± 93.8 241.6 ± 103.7
Males Albumin(g/L) Globulin(g/L) Bil.(lmol/L) Chol.(mmol/L) Creat.(lmol/L) Glu.(mmol/L) Protein(g/L) Triglyc. (mmol/L) BUN (mmol/L)
Group 1 29.56 ± 0.44 25.84 ± 1.63 4.78 ± 0.48 4.226 ± 0.64 24.2 ± 2.9 7.866 ± 0.94 55.4 ± 1.7 0.866 ± 0.15 8.37 ± 1.38
Group 2 28.92 ± 0.75 25.08 ± 1.55 5.36 ± 0.86 4.094 ± 0.49 22.0 ± 2.4 6.468 ± 0.95 54.0 ± 1.6 0.802 ± 0.16 8.21 ± 3.03
Group 3 29.62 ± 1.10 28.18 ± 5.20 5.14 ± 0.49 3.802 ± 0.37 25.8 ± 3.3 6.392 ± 1.25 57.8 ± 5.5 0.840 ± 0.11 11.04 ± 2.84
Group 4 29.30 ± 0.98 27.70 ± 2.79 4.58 ± 0.71 4.176 ± 0.47 21.2 ± 1.6 6.238 ± 0.89 57.0 ± 3.2 0.878 ± 0.22 8.02 ± 1.25
Group 5 28.46 ± 1.13 25.94 ± 1.73 5.08 ± 0.86 3.776 ± 0.77 23.4 ± 3.4 7.638 ± 0.54 54.4 ± 2.1 0.790 ± 0.365 9.42 ± 2.29
Males Ca++(mmol/L) Cl(mmol/L) K+(mmol/L) Na+(mmol/L) ALAT(u/L) AP(u/L) ASAT(u/L) LDH(u/L)
Group 1 2.60 ± 0.11 109.4 ± 0.5 3.84 ± 0.35 151.8 ± 1.8 33.2 ± 18.6 79.4 ± 4.4 105.8 ± 105.5 284.0 ± 183.6
Group 2 2.50 ± 0.11 109.2 ± 1.6 4.00 ± 0.4 150.6 ± 3.0 33.4 ± 9.0 87.6 ± 18.8 72.2 ± 22.9 240.4 ± 64.7
Group 3 2.61 ± 0.105 109.6 ± 2.4 3.82 ± 0.29 151.8 ± 2.6 28.6 ± 6.2 90.4 ± 4.1 67.6 ± 14.2 168.4 ± 14.1
Group 4 2.53 ± 0.09 109.4 ± 1.7 4.16 ± 0.49 152.8 ± 2.3 30.8 ± 6.0 81.4 ± 17.0 69.0 ± 8.2 214.0 ± 58.3
Group 5 2.48 ± 0.14 109.0 ± 1.6 3.91 ± 0.3 151.2 ± 1.3 32.4 ± 6.3 85.6 ± 16.3 70.8 ± 21.2 216.6 ± 65.5
Abbreviations: ALAT, alanine aminotransferase; AP, alkaline phosphatase; ASAT, aspartate aminotransferase; Bil, bilirubin; BUN, blood urea nitrogen; Chol, cholesterol; Creat,
creatinine; Glu, glucose; LDH, lactate dehydrogenase; Triglyc, triglycerides.
a Control.
b DSM 23964 (viable) 1  106 CFU/animal/day.
c DSM 23964(viable) 1  107 CFU/animal/day.
d DSM 23964 (viable) 1  108 CFU/animal/day.
e DSM 23964 (past.) 1  1011 cells/animal/day.
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Table 7
Summary of relative organ weights (g/kg b.w.).
Organs Group 1a Group 2b Group 3c Group 4d Group 5e
Males
Adrenal Left 0.171 ± 0.062 0.183 ± 0.205 0.200 ± 0.100 0.128 ± 0.043 0.182 ± 0.063
Right 0.160 ± 0.083 0.158 ± 0.088 0.198 ± 0.075 0.132 ± 0.051 0.171 ± 0.073
Brain 12.74 ± 0.824 14.297 ± 1.771 14.01 ± 1.096 13.525 ± 1.822 14.378 ± 2.154
Epididymis Left 1.808 ± 0.716 1.830 ± 0.634 1.768 ± 0.313 1.659 ± 0.519 1.820 ± 0.182
Right 1.461 ± 0.265 1.843 ± 0.483 1.956 ± 0.312 1.617 ± 0.369 2.009 ± 0.384*
Gonads Left 3.594 ± 0.431 4.152 ± 0.860 3.532 ± 0.301 3.326 ± 0.536 3.807 ± 0.272
Right 3.603 ± 0.390 4.244 ± 0.561⁄ 3.742 ± 0.410 3.397 ± 0.457 3.779 ± 0.543
Heart 4.985 ± 0.588 5.440 ± 0.695 5.396 ± 0.828 5.182 ± 0.507 5.330 ± 0.620
Kidney Left 8.218 ± 0.912 8.763 ± 1.008 8.649 ± 0.719 8.654 ± 1.114 8.469 ± 1.164
Right 8.108 ± 0.915 8.571 ± 1.391 8.895 ± 0.686 8.570 ± 1.061 9.204 ± 1.216
Liver 48.52 ± 4.09 50.76 ± 4.63 50.08 ± 4.40 50.43 ± 4.33 46.85 ± 6.05
Lungs 6.935 ± 0.851 7.199 ± 1.307 7.253 ± 0.775 7.349 ± 1.239 7.316 ± 1.266
Spleen 2.626 ± 0.707 2.447 ± 0.727 2.996 ± 0.982 2.759 ± 0.979 2.726 ± 0.594
Thymus 1.337 ± 0.296 1.007 ± 0.260 1.181 ± 0.425 1.140 ± 0.232 1.391 ± 0.348
Females
Adrenal Left 0.353 ± 0.098 0.549 ± 0.380 0.396 ± 0.063 0.320 ± 0.085 0.354 ± 0.156
Right 0.358 ± 0.164 0.491 ± 0.334 0.356 ± 0.119 0.318 ± 0.072 0.308 ± 0.101
Brain 18.18 ± 2.024 18.063 ± 2.026 17.710 ± 1.681 17.651 ± 3.098 17.433 ± 1.806
Gonads Left 0.473 ± 0.133 0.627 ± 0.272 0.552 ± 0.184 0.367 ± 0.166 0.436 ± 0.123
Right 0.447 ± 0.183 0.551 ± 0.254 0.507 ± 0.156 0.406 ± 0.171 0.453 ± 0.189
Heart 5.343 ± 0.602 5.229 ± 0.624 5.254 ± 0.587 5.478 ± 0.819 5.610 ± 0.643
Kidney Left 7.696 ± 1.145 7.328 ± 0.719 7.086 ± 0.908 6.778 ± 0.883 6.706 ± 0.438
Right 7.775 ± 0.817 7.342 ± 0.802 7.016 ± 0.895 6.840 ± 0.986 6.908 ± 0.519
Liver 52.55 ± 7.12 49.19 ± 6.74 51.78 ± 4.14 48.90 ± 4.29 56.66 ± 6.07
Lungs 8.739 ± 0.976 7.912 ± 0.709 8.267 ± 1.080 7.906 ± 0.585 8.439 ± 1.304
Spleen 3.358 ± 0.725 3.280 ± 0.946 3.186 ± 0.609 3.425 ± 1.099 3.475 ± 0.790
Thymus 1.606 ± 0.321 1.714 ± 0.559 1.928 ± 0.456 1.776 ± 0.320 1.575 ± 0.394
Uterus 5.582 ± 1.429 6.510 ± 3.073 5.495 ± 2.362 6.394 ± 5.836 5.218 ± 1.310
Data are presented as mean (g/kg b.w.) ± SEM.
a Control.
b DSM 23964 (viable) 1  106 CFU/animal/day.
c DSM 23964(viable) 1  107 CFU/animal/day.
d DSM 23964 (viable) 1  108 CFU/animal/day.
e DSM 23964 (past.) 1  1011 cells/animal/day.
* Statistically signiﬁcant (p < 0.01) difference with group 1 (control).
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4-h exposure. Again, none of the concentrations of B. xylanisolvens
DSM 23964, either viable or pasteurized, produced any statistically
signiﬁcant increase in aberrant cells, resulting in 0% to 1.5% in two
independent experiments. The positive control presented 13.5%
and 16.5% aberrant cells after a 4-h period in two experiments,
respectively. For all B. xylanisolvens DSM 23964 concentrations
tested, no item-related endoreduplication was noted in the exper-
iments with or without metabolic activation. Furthermore, no
signs of cytotoxicity were noted at any tested concentration of B.
xylanisolvens DSM 23964 in the experiments with and without
metabolic activation (data not shown).3.4. Ninety-day oral toxicity study in mice
No mortality occurred during the study. None of the mice
treated or untreated exhibited any clinical sign on cage-side
observation. The results of the functional battery observations
and motor activity tests also did not reveal any test item-related
changes (data not shown). Food and water consumption as well
as body weight gain did not differ between the treated groups
(Fig. 1). The hematological examination revealed no statistically
signiﬁcant differences between treated groups and the control
group (Table 5). Noteworthy, the number of leucocytes identiﬁed
in group 2 animals and the respective parameters of the differ-
ential blood count were relatively low compared to the control
group and other treatment groups. However, all values were still
in the normal range, and the difference to the control group wasnot statistically signiﬁcant. The clinical biochemical parameters
also remained unaffected by the treatments. The observed
decreased plasma ASAT concentrations in females of group 4
were considered to be fortuitous since there was no evidence
of a dose–response relationship, and since there were no corre-
sponding changes observed in male mice (Table 6). The ophthal-
mological examination revealed no pathological observations for
any group of mice. Organ weights and their physical appearance
were not affected by the treatment (Table 7). The observed
statistically signiﬁcant difference between males of group 2
and group 5 and the control group for the right epididymis
and right gonad, respectively, were considered to be incidental.
No dose–response relationships were detected, and in each case
statistical signiﬁcance could only be identiﬁed for one of the pair
organs. Furthermore, the histopathological examination of stan-
dard organs and tissues revealed no treatment-related changes
(Table 8). All microscopic ﬁndings noted were within the normal
range for animals of this strain and age.3.5. In vivo pathogenicity of B. xylanisolvens DSM 23964 (abscess
formation)
The bacterial viability, concentration and purity of the injected
test mixture solutions were determined retrospectively on the
remaining material after injection. The bacterial viability and
concentration were conﬁrmed through plating on agar plates un-
der anaerobic incubation conditions (data not shown). Multiplex
PCR conﬁrmed the presence of the desired bacterial strain and
Fig. 1. Body weight and food consumption of mice during the 90 day oral toxicity study. (A) Body weights of male Crl:NMRI mice. (B) Body weights of female Crl:NMRI mice.
(C) Food consumption of male Crl:NMRI mice. (D) Food consumption of female Crl:NMRI mice. Mean values per group: Group1 (0), Group2 (1  106), Group3 (1  107),
Group4 (1  108) CFU’s of Bacteroides xylanisolvens DSM 23964/animal/day. Group5 (1  1011) B. xylanisolvens DSM 23964 pasteurized/animal/day. Differences are not
statistically signiﬁcance according to Dunnett’s test.
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Common contaminations could be excluded through plating of
each test item on an appropriate agar plate and incubation under
aerobic conditions.
In two separate experiments, mice injected with a high dose of
B. xylanisolvens DSM 23964 did not develop more or larger ab-
scesses than the negative control (barium sulfate + sterile rat
feces). In contrast, high concentrations of B. fragilis RMA 6971 in-
duced the formation of more and larger abscesses (data not
shown). After 7 days, 2 abscesses per animal were taken under
sterile conditions, punctured, and the contents submitted to DNA
extraction. The presence of B. xylanisolvens DSM 23964 or B. fragilis
RMA 6791 in the abscesses was evaluated by means of species-spe-
ciﬁc PCRs. As shown in Fig. 3, B. fragilis RMA 6971 could be de-
tected in all abscesses isolated from groups 2, 4 and 6 injected
with 5.0  106 to 1.0  109 CFUs of B. fragilis per ml, respectively.
In contrast, independent of the bacterial concentration injected,
B. xylanisolvens DSM 23964 could not be detected in any of the ana-
lyzed abscesses, suggesting that the strain was either absent or
present at an amount below the detection limit of our species-spe-
ciﬁc PCRs. These results indicate that B. xylanisolvens DSM 23964
does not induce the formation of abscesses, and that it is quickly
eliminated by the immune system after i.p. injection.4. Discussion
We have recently isolated a novel B. xylanisolvens strain (DSM
23964) and demonstrated it to be free from any virulence factorsknown for the genus Bacteroides (Ulsemer et al. 2011, in press).
The present study aimed to complete the safety assessment of B.
xylanisolvens DSM 23964 through toxicological and pathological
studies.
As no guidelines explicitly indicate the doses of probiotic bacte-
ria to be tested, the genotoxicity and toxicity of a high daily dose of
pasteurized or viable B. xylanisolvens DSM 23964 cells were as-
sessed. Although lyophilized pasteurized bacteria could be pro-
duced to a ﬁnal concentration of 4  1012 cells per gram,
technical limitations prevented the use of such a concentration
for viable cells. Indeed, as reported for many other microorganisms
(Berner and Viernstein, 2006; Miyamoto-Shinohara et al., 2000),
the lyophilization and/or rehydration process signiﬁcantly affected
the viability of our strain, limiting the post-rehydration concentra-
tion to 4  109 CFUs/g. Noteworthy, the integrity of the cell was
not affected (data not shown).
Both the Ames test and the in vitro chromosomal aberration
assay demonstrated that neither the viable nor the pasteurized
form of the strain DSM 23964 exert any mutagenic or genotoxic
effects.
Furthermore, a 90-days sub-chronic oral gavage study in mice
with doses of up to 1  108 CFUs live bacteria/animal/day or
1  1011 pasteurized bacteria/animal/day demonstrated the
absence of any toxic effect of strain DSM 23964. Indeed, extensive
clinical observations, hematological data, clinical chemistry
parameters, as well as post mortem macroscopic and histopatholo-
gical examinations of organs revealed no adverse effects in either
female or male mice for both viable or pasteurized bacteria of
strain DSM 23964. Taking into account a mean body weight of
Table 8
Summary of histopathological ﬁndings.
Organ Male Female
Gr.1a Gr.4b Gr.5c Gr.1a Gr.4b Gr.5c
Adrenal (I) 9 10 10 10 10 10
Foamy cells, zona reticularis 2 2 1 8 10 10
Subcapsular hyperplasia – – 1 3 6 6
Adrenal (II) 9 9 10 10 10 10
Capillary ectasia – 1 – 7 10 10
Foamy cells, zona reticularis 2 3 3 7 5 7
Subcapsular hyperplasia 2 4 –* – – –
Duodenum. 9 10 10 10 10 10
Subepithelial oedema – – – – 1 –
Epididymis (II) 10 9 10 10 10 10
Interstit.lymphocytic inﬁltr. 1 – 2 – – –
Eye (I), incl. optic nerve 10 10 10 10 10 10
Limbus: Mixed cell inﬁltr. 1 1 1 1 1 –
Retrobulbar,mixed cell inﬁlt. 2 3 1 1 1 –
Destruction 1 – – – 1 –
Eye (II), incl. optic nerve 10 10 10 10 10 10
Limbus: Mixed cell inﬁltr. – 1 – – 1 2
Retrobulbar,mixed cell inﬁlt. – – 1 – 1 2
Destruction – – 1 1 1 0
Gall bladder. 10 10 8 10 10 10
Mixed cell. inﬁltration – – – 1 – –
Subepithelial lymph.inﬁltr. 3 3 3 2 2 4
Epithelial vacuolisation – 1 – – 1 –
Heart (3 sections) 10 10 10 10 10 10
Mixed cell inﬁltration 2 1 – – – –
Granulation tissue 1 1 1 – – –
Lympho-histiocytic inﬁltr. 1 – – – 1 –
Brown.pigm.endo.cells/macroph. – 1 – – – –
Heart (scarlet R). 10 10 10 10 10 10
Fatty inﬁltraion – – – 3 3 1
Jejunum. 9 10 10 10 10 10
Granulocytic inﬁltration – – – – 1 –
Kidney (I) and ureter 10 10 10 10 10 10
Congestion – 1 – 1 – –
Hyaline tubular casts – 2 – 1 1 2
Lympho-histiocytic inﬁltr. 5 4 5 3 2 4
Basophilic tubular cells 1 1 2 – 1 –
Kidney (II) and ureter 10 10 10 10 10 10
Congestion – 1 – 1 – –
Mineralization 1 – – 1 – –
Hyaline tubular casts 1 1 – 1 1 –
Lympho-histiocytic inﬁltr. 5 5 9 5 4 6
Basophilic tubular cells – 1 – – – –
Kidney I (scarlet R) 10 10 10 10 10 10
Fatty inﬁltr., tubuli 4 3 4 5 5 3
Larynx 10 10 9 8 9 10
Subepi.lympho-histioc.inﬁltr. – – – – 1 –
Liver. 10 10 10 10 10 10
Lympho-histiocytic inﬁltr. 6 3 3 5 6 5
Mixed-cellular inﬁltration 1 1 3 1 – –
Brownish pigment,macrophages – – 1 1 – –
Glycogen incr./plant c.struct. 6 6 4 5 2 6
Necrosis – – – 1 – –
Centril./diff.hepat.hypertr. 10 10 10 9 9 10
Liver (scarlet R) 10 10 10 10 10 10
Fatty inﬁltr., single cells – 4 1 – – –
Diffuse fatty inﬁltration 4 3 5 4 8 5
Peripheral fatty inﬁltration 4 2 3 – – –
Centrilobul. fatty inﬁltr. 2 1 1 6 2 5
Lungs (w.bronchi/bronchioles) 10 10 10 10 10 10
Foreign body bronchopneumonia – – – – 1 –
Haemorrhage 1 1 1 3 1 1
Lymph node (cervical) 8 8 5 8 7 7
Haemorrhage/erythrophagocytos – – – 1 – –
Sinus histiocytosis 8 6 5 8 7 7
Lymphoid hyperplasia 8 7 5 7 7 6
Plasmocytosis 1 – – – – –
Yellow–brown pigm.in macroph. 7 5 5 8 7 6
Lymph node (mesenteric 10 10 10 10 9 10
Haemorrhage/erythrophagocytos. – – 1 – – –
Sinus histiocytosis 10 10 10 10 9 9
Lymphoid hyperplasia 10 10 10 10 9 10
Granulocytic inﬁltration – – – – – 1
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Table 8 (continued)
Organ Male Female
Gr.1a Gr.4b Gr.5c Gr.1a Gr.4b Gr.5c
Yellow–brown pigm.in macroph. 3 3 4 5 4 3
Ovary I (incl. oviduct) – – – 10 10 10
Follicular cysts – – – – – 1
Pancreas 10 10 10 10 10 10
Acinar atrophy and ﬁbrosis – – – – – 2
Pituitary 10 10 10 10 9 10
Cysts in adenohypophysis – – – 1 – –
Preputial gland 0 1 1 – – –
Abscess – 1 1 – – –
Prostate 10 10 10 – – –
Lymphocytic inﬁltration 2 3 4 – – –
Salivary glands (3 sections) 10 10 10 10 10 10
Lympho-histiocytic inﬁltr. 3 3 1 4 4 4
Stomach. 10 10 10 10 10 10
Mixed cell.inﬁltr.,subepith – – – – 1 1
Ulcer glandular mucosa 1 – – – – –
Thymus. 10 10 10 10 10 10
Haemorrhage 1 – – – – –
Lymphoid hyperplasia 1 – 1 – – –
Cystic transformation – – – – – 1
Thyroid (I) 10 9 8 10 10 10
Follicular cyst 1 – – – – –
Lymphocytic inﬁltration – – – – 1 –
Chronic inﬂammation – 1 – 1 – –
Macrofollicular structure – – 1 – – –
Thyroid (II) 10 7 7 7 10 9
Lymphocytic inﬁltration – – – – 1 –
Macrofollicular structure – – 1 1 – –
Trachea 10 9 7 8 9 9
Subepi.lympho-histioc.inﬁltr. 1 2 1 – 1 2
Urinary bladder 10 10 10 9 10 10
Granulocytic inﬁltration – – – – – 1
Proteinaceous content 1 1 2 – – –
Lympho-histiocytic inﬁltr. – – 1 3 1 1
Chronic cystitis – – 1 – – –
For each group:
- The number assigned to each organ indicates the number of organ analyzed.
- The numbers assigned to each ﬁnding indicates the number of the analyzed organs that presented the corresponding ﬁnding.
Further organs that were analyzed but did not show any ﬁnding: aorta abdominalis, bone marrow, mammary gland, nerve (sciatic), oesophagus, ovary (II), skin, testicles,
uterus and vagina.
a Control.
b DSM 23964 (viable) 1  108 CFU/animal/day.
c DSM 23964 (past.) 1  1011 cells/animal/day.
* signiﬁcantly different from Group 4 (p 6 0.05).
Fig. 2. Detection of potential contamination in injected solutions by multiplex
species-speciﬁc PCR. Lanes: 1, positive control (B. xylanisolvens DSM 23964); 2,
Solution 2 (1  109 Bacteroides fragilis RMA 6791/ml); 3, Solution 3 (1  109 B.
xylanisolvens DSM 23964/ml); 4, Solution 4 (1.5  108 Bacteroides fragilis RMA 6791/
ml); 5, Solution 5 (1.5  108 B. xylanisolvens DSM 23964/ml); 6, Solution 6 (5  106
Bacteroides fragilis RMA 6791/ml); 7, Solution 7 (5  106 B. xylanisolvens DSM 23964/
ml), 8, positive control (Bacteroides fragilis RMA 6791); 9, Solution 1 (control group).
Contamination controls: lane 10, mixture of 90% Bacteroides fragilis RMA 6791 and
10%B. xylanisolvensDSM23964; lane 11,mixture of 10%Bacteroides fragilisRMA6791
and 90% B. xylanisolvens DSM 23964. Lane 12, 1 kb DNA ladder (Fermentas).
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3.3  109 CFUs or 3.3  1012 pasteurized bacteria per kg bodyweight, corresponding to doses of 2.3  1011 CFUs or 2.3  1014
pasteurized bacteria, respectively, for an average 70 kg human
being. The value obtained for viable strain DSM 23964 cells was
within the range of typical values for Lactobacillus probiotic strains
(Jia et al., 2011; Yakabe et al., 2009). The NOAEL value obtained for
the pasteurized form of strain DSM 23964 would actually repre-
sent more than the total amount of bacteria estimated to inhabit
the human colon.
Although we have previously demonstrated that the strain B.
xylanisolvens DSM 23964 does not contain any of the virulence fac-
tors described for the genus Bacteroides (Ulsemer. et al. 2011.), its
in vivo pathogenicity had not been previously examined. A well ac-
cepted model to study the pathogenicity of potential opportunist
pathogens like B. fragilis is the ‘‘intraperitoneal abscess formation
model’’ (McConville et al., 1981; Onderdonk et al., 1984; Thadepalli
et al., 2001), in which viable microorganism(s) or substances there-
of are intraperitoneally injected in mice together with sterilized rat
feces extracts, to some extent mirroring a bacterial invasion under
extremely unfavorable and unlikely conditions. Using freshly pro-
duced viable cells, it was demonstrated that, in contrast to a known
clinical isolate of B. fragilis, the injection of up to 4.6  109 CFUs of
B. xylanisolvens DSM 23964 per kilogram body weight did not have
any pathological effect, and that B. xylanisolvens DSM 23964 was
indeed quickly eradicated by the immune system.
Fig. 3. Species-speciﬁc PCR of isolated DNA from punctured Abscesses. (A) Detection of B. xylanisolvens in abscesses of animals, which injected with B. xylanisolvens DSM
23964. Lanes: 1, 100 bp DNA ladder (Fermentas); 2 and 3, Group 3 (4.6  109 B. xylanisolvens DSM 23964/kg bw); 4 and 5, Group 5 (6.9  108 B. xylanisolvens DSM 23964/kg
bw); 6 and 7, Group 7 (2.3  107 B. xylanisolvens DSM 23964/kg bw); 8, positive control (B. xylanisolvens DSM 23964); 9, negative control (water). B) Detection of Bacteroides
fragilis in abscesses of animals, which injected with Bacteroides fragilis RMA 6791. Lanes: 1, 100 bp DNA ladder (Fermentas); 2 and 3, Group 2 (4.6  109 Bacteroides fragilis
RMA 6791/kg bw); 4 and 5, Group 4 (6.9  108 Bacteroides fragilis RMA 6791/kg bw); 6 and 7, Group 6 (2.3  107 Bacteroides fragilis RMA 6791/kg bw), 8, positive control
(Bacteroides fragilis RMA 6791); 9, negative control (Water); 10, 1 kb DNA ladder (Fermentas).
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In summary, the strain B. xylanisolvens DSM 23964 was shown
(i) not to possess any of the virulence factors previously described
for the genus Bacteroides (Ulsemer et al., 2011 submitted), (ii) not
to carry any mutagenic or clastogenic activities, either in its viable
or in its pasteurized form, (iii) not to exert any toxicological effect,
either in its viable or in its pasteurized form, and at concentrations
up to 3.3  1012 pasteurized bacteria/kg body weight, (iv) not to
present any pathogenic properties in vivo, and (v) to be sensitive
to the defense system of the host.
The results of these studies support the safety of use of B. xylan-
isolvens DSM 23964 in both its viable and its pasteurized forms in
food.
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